Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antiviral drug |
| gptkbp:administeredBy |
gptkb:elbasvir
|
| gptkbp:approvalYear |
2016
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
J05AP53
|
| gptkbp:brand |
gptkb:Zepatier
|
| gptkbp:CASNumber |
1350514-68-9
|
| gptkbp:contraindication |
severe liver impairment
concomitant use with strong CYP3A inducers |
| gptkbp:developedBy |
gptkb:Merck_&_Co.
|
| gptkbp:hasMolecularFormula |
C38H50N6O9S
|
| https://www.w3.org/2000/01/rdf-schema#label |
grazoprevir
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
NS3/4A protease inhibitor
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
fatigue headache |
| gptkbp:usedFor |
gptkb:hepatitis_C
|
| gptkbp:bfsParent |
gptkb:Zepatier
|
| gptkbp:bfsLayer |
6
|